Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01712490 · OUTCOME

Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma · Source last updated 2026-02-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Baseline up to 30 days after last dose of study drug (approximately 1 year)

Analysis population: The safety population included all enrolled participants who received at least 1 dose of any study drug.

Groups in this outcome

A+AVD

Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.

ABVD

Doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A+AVD662
ABVD659

Reported measurements

TEAE
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
A+AVD653Not reportedNot reportedNot reportedNot reported
ABVD646Not reportedNot reportedNot reportedNot reported
SAE
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
A+AVD284Not reportedNot reportedNot reportedNot reported
ABVD178Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        653
      2. group Id
        OG001
        value
        646
    title
    TEAE
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        284
      2. group Id
        OG001
        value
        178
    title
    SAE
denoms
  1. counts
    1. group Id
      OG000
      value
      662
    2. group Id
      OG001
      value
      659
    units
    Participants
groups
  1. description
    Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.
    id
    OG000
    title
    A+AVD
  2. description
    Doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.
    id
    OG001
    title
    ABVD
param Type
NUMBER
population Description
The safety population included all enrolled participants who received at least 1 dose of any study drug.
reporting Status
POSTED
time Frame
Baseline up to 30 days after last dose of study drug (approximately 1 year)
title
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice